or Try an Advanced Search...

    Technical Analysis for ONC - Oncolytics Biotech Inc.

    Grade Last Price % Change Price Change
    C 1.410 -4.73% -0.070
    ONC closed up 6.47 percent on Tuesday, November 19, 2024, on 60 percent of normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical ONC trend table...
    Date Alert Name Type % Chg
    Crossed Above 200 DMA Bullish -4.73%
    Stochastic Buy Signal Bullish -4.73%
    Oversold Stochastic Weakness -4.73%
    NR7 Range Contraction 1.44%
    Narrow Range Bar Range Contraction 1.44%
    Oversold Stochastic Weakness 1.44%
    Lower Bollinger Band Walk Weakness 2.17%
    Down 3 Days in a Row Weakness 2.17%
    Lower Bollinger Band Touch Weakness 2.17%
    Oversold Stochastic Weakness 2.17%
    Older End-of-Day Signals for ONC ...

       Recent Intraday Alerts

    Alert Time
    Down 1 ATR 30 minutes ago
    Down 5% about 2 hours ago
    Down 3% about 3 hours ago
    Fell Below 200 DMA about 3 hours ago
    Gap Down Partially Closed about 4 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    ONC Chart by TradingView
    Basic chart:

    Profile

    Oncolytics Biotech Inc. Description

    Oncolytics Biotech Inc. is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company's clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials. The Company focuses on the registration of REOLYSIN in approximately two indications, including the neoadjuvant treatment of muscle-invasive bladder cancer and the treatment of glioblastoma. The Company has conducted a single arm United States Phase II non-small cell lung cancer (NSCLC) trial and a single arm United States Phase II pancreatic cancer trial for REOLYSIN. The Company is also engaged in conducting a Phase Ib trial for REOLYSIN and chemotherapy in combination with pembrolizumab in its Checkpoint Inhibitor Program.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Health Medicine Clinic Cancer RTT Therapy Oncology Clinical Trial Lung Cancer Blastoma Chemotherapy Non Small Cell Lung Cancer Glioblastoma

    Is ONC a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 13 Oncolytics Biotech Inc (ONCY) Q3 2024 Earnings Call Highlights: Strategic Advances and ...
    Nov 12 Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights
    Nov 11 Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights
    Oct 7 ONCY Stock Up on Regulatory Update From Breast Cancer Program
    Oct 7 Oncolytics targets accelerated approval for oncolytic virus therapy
    Oct 4 Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path
    Sep 19 Oncolytics Biotech Reports "Favorable" Results for BRACELET-1 Breast Cancer Study
    Sep 19 Oncolytics Biotech® Reports Favorable Results for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study
    Sep 6 Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September
    Aug 12 Sernova Corp. Announces Appointment of New Chief Executive Officer
    See more ONC news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 2.32
    52 Week Low 1.15
    Average Volume 128,773
    200-Day Moving Average 1.446
    50-Day Moving Average 1.495
    20-Day Moving Average 1.564
    10-Day Moving Average 1.470
    Average True Range 0.095
    RSI (14) 46.24
    ADX 19.43
    +DI 20.841
    -DI 20.075
    Chandelier Exit (Long, 3 ATRs) 1.604
    Chandelier Exit (Short, 3 ATRs) 1.656
    Upper Bollinger Bands 1.777
    Lower Bollinger Band 1.351
    Percent B (%b) 0.3
    BandWidth 27.276
    MACD Line -0.038
    MACD Signal Line -0.012
    MACD Histogram -0.026
    Fundamentals Value
    Market Cap 64.08 Million
    Num Shares 43.3 Million
    EPS -1.02
    Price-to-Earnings (P/E) Ratio -1.46
    Price-to-Sales 0.00
    Price-to-Book 7.41
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.630
    Resistance 3 (R3) 1.613 1.547 1.605
    Resistance 2 (R2) 1.547 1.508 1.555 1.597
    Resistance 1 (R1) 1.513 1.485 1.530 1.530 1.588
    Pivot Point 1.447 1.447 1.455 1.455 1.447
    Support 1 (S1) 1.413 1.408 1.430 1.430 1.372
    Support 2 (S2) 1.347 1.385 1.355 1.363
    Support 3 (S3) 1.313 1.347 1.355
    Support 4 (S4) 1.330